Progress in Cancer Research: Inhibitory Mechanisms and Effects of Erianin on Pancreatic Cancer Background and Significance of the Study Pancreatic cancer is a malignant tumor of the digestive tract, characterized by inconspicuous early symptoms, high malignancy, and limited efficacy of conventional radiotherapy and chemotherapy, leading to a very h...

Background Pancreatic Ductal Adenocarcinoma (PDAC) is a malignancy with a highly immunosuppressive tumor microenvironment (TME), showing strong resistance to immune checkpoint blockade (ICB) therapies, such as anti-PD-1 and anti-CTLA-4 treatments. Myeloid-Derived Suppressor Cells (MDSCs) derived from tumors play a critical role in tumor immune supp...

Research Report on the Mechanism of BAG6 Restricting Pancreatic Cancer Progression Research Background Pancreatic Ductal Adenocarcinoma (PDAC) has an extremely poor prognosis, with a median survival of only 6 months, urgently requiring new treatment methods. In recent years, studies have found that extracellular vesicles (EVs) released by tumor cel...

Research Report: The Regulatory Role of ROR2 in Pancreatic Cancer Cell Plasticity Background Introduction Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with most patients lacking the possibility of a cure. This is partly due to the difficulty in early detection. One of the characteristics of PDAC is its extensive tumor cell heterogene...

Interactive Mechanisms Between Cancer Cells and Macrophages Facilitate Pancreatic Cancer Cachexia Background Pancreatic cancer is currently the third leading cause of cancer-related death in the United States and is expected to become the second leading cause of cancer death within the next decade. Unfortunately, more than 80% of pancreatic cancer ...